Search results for "portion"

showing 10 items of 902 documents

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

2012

The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa).High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to…

OncologyPCA3MaleCancer Researchmedicine.medical_specialtyPrognosiPSA progressionValue (computer science)Kaplan-Meier EstimateNuclear matrix proteins; Prognosis Prostate cancer; PSA progressionurologic and male genital diseasesNuclear Matrix-Associated ProteinFollow-Up StudieProstate cancerNuclear Matrix-Associated ProteinsInternal medicinemedicineCluster AnalysisHumansElectrophoresis Gel Two-DimensionalNuclear matrix proteinMultivariate AnalysiProportional Hazards ModelsNuclear matrix proteinsHematologyCluster AnalysiProstate cancerProportional hazards modelbusiness.industryProstatic NeoplasmsPSA PROGRESSIONGeneral MedicineProstate-Specific AntigenNuclear matrixmedicine.diseasePrognosisProstate-specific antigenOncologyMultivariate AnalysisDisease ProgressionProportional Hazards ModelbusinessFollow-Up StudiesHuman
researchProduct

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

2020

Contains fulltext : 218279.pdf (Publisher’s version ) (Open Access) Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (>/=0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 …

OncologyPROBABILITIESMalePROGNOSISCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]NPM1 MUTATIONBiochemistryEuropean LeukemiaNetchemistry.chemical_compoundALLELIC RATIOAMLRisk FactorsGene Duplicationhemic and lymphatic diseasesMidostaurinFLT3Myeloid NeoplasiaHematopoietic Stem Cell TransplantationMyeloid leukemiaNuclear ProteinsHematologyCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenEuropeLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeTandem Repeat SequencesFemaleNucleophosminmedicine.medical_specialtyNPM1GenotypeImmunologyYOUNGER ADULTSInternal medicineWhite blood cellmedicineNORMAL CYTOGENETICSHumansGenetic Predisposition to DiseaseProportional Hazards ModelsProportional hazards modelbusiness.industryCell BiologyINTERNAL TANDEM DUPLICATIONTransplantationchemistryfms-Like Tyrosine Kinase 3Multivariate AnalysisbusinessSettore MED/15 - Malattie del Sangue
researchProduct

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients

2012

Diverse polymorphisms have been associated with the predisposition to develop cancer. On fewer occasions, they have been related to the evolution of the disease and to different responses to treatment. Previous studies of our group have associated polymorphisms on genes related to oxidative stress (rs3736729 on GCLC and rs207454 on XDH) and DNA damage repair (rs1052133 on OGG1) with a predisposition to develop breast cancer. In the present work, we have evaluated the hypothesis that these polymorphisms also play a role in a patient’s survival. A population-based cohort study of 470 women diagnosed with primary breast cancer and a median follow up of 52.44 months was conducted to e…

OncologyPathologyDNA Repairlcsh:ChemistryGenotypeMedicineProgesterone Receptor Negativegenetic variants; GCLC; XDH; OGG1; breast cancer; survivalOGG1lcsh:QH301-705.5SpectroscopyAged 80 and overeducation.field_of_studyGeneral MedicineMiddle AgedNeoplasm ProteinsComputer Science ApplicationsGCLCSurvival RateGCLCFemaleAdultmedicine.medical_specialtyPopulationBreast NeoplasmssurvivalArticleDisease-Free SurvivalCatalysisInorganic ChemistryBreast cancerbreast cancerMedian follow-upInternal medicineXDHHumansPhysical and Theoretical ChemistryeducationMolecular BiologyAgedPolymorphism GeneticProportional hazards modelbusiness.industrygenetic variantsOrganic ChemistryCancermedicine.diseaseOxidative Stresslcsh:Biology (General)lcsh:QD1-999businessDNA DamageFollow-Up StudiesInternational Journal of Molecular Sciences
researchProduct

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

2020

Abstract Background & Aims Radiological progression patterns to first‐line sorafenib have been associated with post‐progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second‐ and later‐line settings. This post hoc analysis of REACH and REACH‐2 examined outcomes by radiological progression patterns in the second‐line setting of patients with advanced hepatocellular carcinoma treated with ramucirumab or placebo. Methods Patients with advanced hepatocellular carcinoma, Child‐Pugh A and Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib were randomized to receive ramucirumab 8mg/kg or place…

OncologySorafenibLiver CancerMalemedicine.medical_specialtyCarcinoma HepatocellularramucirumabPopulationRadioteràpiaAntineoplastic AgentsPlaceboAntibodies Monoclonal HumanizedRamucirumabLesionCàncer de fetge03 medical and health sciencesbest supportive care0302 clinical medicineInternal medicinePost-hoc analysisMedicineHumanseducationdisease progression patternseducation.field_of_studyHepatologyRadiotherapybusiness.industryProportional hazards modelLiver NeoplasmsMiddle AgedSorafenibmedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyOriginal Articlemedicine.symptombusinesspost‐progression survivalnew extrahepatic lesionLiver cancermedicine.drug
researchProduct

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BS…

2012

ABSTRACT Background Tumor EGFR and KRas mutations are both predictive and prognostic biomarkers in patients with advanced NSCLC. We analyzed the correlation between these biomarkers and treatment outcomes in a phase III trial of 3rd/4th line sorafenib in patients with NSCLC. Methods The global, randomized, placebo-controlled MISSION trial enrolled 703 patients with advanced relapsed/refractory NSCLC of predominantly non-squamous histology. The primary study endpoint was overall survival (OS). EGFR and KRas mutations were analyzed in archival tumor samples and in circulating tumor DNA isolated from plasma. Results Tumor and/or plasma mutation data were available from 347 patients (49%). EGFR…

OncologySorafenibmedicine.medical_specialtyProportional hazards modelbusiness.industryHematologymedicine.disease_causePlacebomedicine.diseaseBreast cancerOncologyEgfr mutationInternal medicineMedicineBiomarker (medicine)KRASStage (cooking)businessmedicine.drugAnnals of Oncology
researchProduct

Dose-response relationship in the context of a maintenance randomized control trial: reanalysis of the PRODIGE 9 trial

2019

Introduction The dose-response relationship is considered as one of the major criteria when the causality of a relationship between an exposure and an outcome is discussed. This criterion is mainly studied in observational studies but may be also of interest in Randomized Controlled Trial (RCT), particularly if the administered dose of treatment varies over time and between patients. Maintenance trials with a long follow-up meet these characteristics. We reanalyzed a maintenance trial in digestive oncology (PRODIGE 9 trial) in order to explore the dose-response relationship between the maintenance treatment and overall survival (OS). Methods The PRODIGE 9 study was a maintenance trial asses…

Oncologyeducation.field_of_studymedicine.medical_specialtyRandomizationEpidemiologybusiness.industryProportional hazards modelPopulationPublic Health Environmental and Occupational HealthCumulative ExposureContext (language use)Lower risklaw.inventionRandomized controlled triallawInternal medicineMedicineObservational studybusinesseducationRevue d'Épidémiologie et de Santé Publique
researchProduct

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

2009

Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. Objective To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen. Design, Setting, and Patients Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer. The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (9…

Oncologymedicine.medical_specialtyAntineoplastic Agents HormonalGenotypeBreast NeoplasmsArticleBreast cancerInternal medicinemedicineHumansskin and connective tissue diseasesSurvival analysisProportional Hazards ModelsPolymorphism GeneticProportional hazards modelbusiness.industryHazard ratioCancerGeneral Medicinemedicine.diseaseAntiestrogenSurvival AnalysisTamoxifenPhenotypeTreatment OutcomeEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsFemaleBreast diseasebusinessTamoxifenmedicine.drug
researchProduct

Detection methods predict differences in biology and survival in breast cancer patients

2012

Abstract Background The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences. Methods For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors. Results After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more …

Oncologymedicine.medical_specialtyCancer ResearchSurvivalProliferationBreast NeoplasmsApoptosisKaplan-Meier Estimatemedicine.disease_causelcsh:RC254-282Breast cancerBreast cancerSurgical oncologyInternal medicineDetection methodsmedicineGeneticsHumansMammographyEarly Detection of CancerProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelDisease progressionCase-control studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseImmunohistochemistryOncologyCase-Control StudiesDisease ProgressionImmunohistochemistryFemalebusinessCarcinogenesisMammographyResearch Article
researchProduct

Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy.

2020

<b><i>Introduction:</i></b> Immunoglobulin κC (IGKC)-positive tumor-infiltrating plasma cells are associated with better prognosis in node-negative breast cancer patients without adjuvant systemic therapy. In the present study we evaluated the prognostic significance of IGKC in breast cancer patients treated with adjuvant chemotherapy ± tamoxifen. <b><i>Methods:</i></b> IGKC expression was immunohistochemically analyzed in 193 breast cancer patients who were treated with adjuvant chemotherapy, either with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) between 1993 and 2001 wit…

Oncologymedicine.medical_specialtyChemotherapyCyclophosphamideProportional hazards modelbusiness.industrymedicine.medical_treatmentHazard ratiomedicine.diseaseLog-rank testBreast cancerOncologyInternal medicinemedicineSurgerybusinessTamoxifenEpirubicinmedicine.drugResearch ArticleBreast care (Basel, Switzerland)
researchProduct